Explore the vast range of titles available.

Cytomegalovirus (CMV) infection is a significant clinical concern in newborns, immunocompromised patients with acquired immunodeficiency syndrome (AIDS), and patients undergoing immunosuppressive therapy or chemotherapy. CMV infection affects many organs, such as the lungs, digestive organs, the central nerve system, and eyes. In addition, CMV infection sometimes occurs in immunocompetent individuals. CMV ocular diseases includes retinitis, corneal endotheliitis, and iridocyclitis. CMV retinitis often develops in infected newborns and immunocompromised patients. CMV corneal endotheliitis and iridocyclitis sometimes develop in immunocompetent individuals. Systemic infections and CMV ocular diseases often require systemic treatment in addition to topical treatment.

Background Micro‐focused ultrasound (MFUS) converts the mechanical energy of high‐frequency vibrations into thermal energy and induces collagen remodeling through thermal effects to achieve skin tightening and lifting. However, when employed for periocular skin treatment, MFUS carries a potential risk of ocular injury, which deserves high attention from cosmetic surgeons. Aims This article reports a case of a young female patient who developed transient visual acuity decline with iridocyclitis and residual corneal leukoma after MFUS treatment on the periocular skin. Patient A 32‐year‐old female patient underwent facial MFUS treatment at a cosmetic clinic to improve facial skin laxity. During the treatment of the right periocular skin, the patient developed right eye pain and visual acuity decline. The patient was treated with nonsteroidal anti‐inflammatory drugs (NSAIDs) and glucocorticoids in the right eye and followed up for 3 months. The visual acuity of the right eye improved, but a permanent corneal leukoma persisted. Results While MFUS treatment targeting the periorbital area can improve skin laxity, it poses a risk of corneal injury and iridocyclitis. After the treatment, the iridocyclitis resolved, but a permanent corneal leukoma remained. Conclusions Periocular MFUS treatment carries the risk of irreversible thermal damage to ocular tissues. Cosmetic surgeons must strictly determine the intensity threshold for periocular MFUS and ensure proper application of eye‐protective devices.

PurposeTo investigate the outcome of mitomycin C (MMC)-augmented trabeculectomy with subconjunctival bevacizumab in the management of Fuchs heterochromic iridocyclitis (FHI)-related glaucoma in 1-year follow-up period.MethodsThis retrospective study included 50 eyes with FHI-related glaucoma those had underwent initial trabeculectomy with MMC (0.2 mg/ml—3 min). Thirty-one of them had single-dose bevacizumab injection (1.25 mg/0.05 ml) into the bleb area just at the end of the surgery, while 19 eyes did not have. The intraocular pressure (IOP) and the mean number of anti-glaucomatous medications were evaluated. The IOP value ≤ 21 mmHg was defined as complete or qualified surgical success in terms of using medical anti-glaucomatous treatment. Bleb height and vascularity were evaluated with Indiana bleb grading system. Paired sample t test, t test, Chi-square and Kolmogorov–Smirnov tests were used for statistical analysis.ResultsThe preoperative IOP values of bevacizumab and without bevacizumab groups were 32.8 ± 4.5 mmHg and 32.8 ± 4.5 mmHg, respectively, and they decreased to 17.5 ± 4.6 mmHg and 17 ± 5.2 mmHg at the final visit (p < 0.001 for all values). There were no significant differences in postoperative IOP and the number of medications between the groups at the final visit. In bevacizumab group, complete success was achieved in 100% within the third month but decreased to 22.5% (complete) and 74.1% (qualified) at the first year. In the other group (without bevacizumab group), complete success was achieved in 94.7% within the third month but decreased to 15.8% (complete) and 84.2% (qualified) at the first year.ConclusionInitial trabeculectomy with MMC and subconjunctival bevacizumab injection was found to have lower rates of complete success with relatively acceptable qualified success rates in the management of FHI-related glaucoma. Subconjunctival bevacizumab was not found to have additional effect to improve the surgical success.

A 68-year-old man presented with diminution of distance and near vision in the right eye for a duration of 1 month postblunt trauma with a stick. On examination, his visual acuity in the right eye was 20/320 and near vision was

Journal Article

Share this book

Add to My Shelf